| 1 |
韩锐, 贾立华, 刘泽源, 等. 几种常见免疫抑制剂的研究进展[J]. 中国药业,2011,20(13):1-4.
|
| 2 |
Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults [J].Kidney Int,2011,80(8):868-878.
|
| 3 |
Goumenos DS, Tsagalis G, El Nahas AM,et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis:a five-year follow-up study [J]. Nephron Clin Pract, 2006, 104(2): c75-c82.
|
| 4 |
Schieppati A, Perna A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome [J]. Cochrane Database Syst Rev,2004, (4):CD004293.
|
| 5 |
Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome [J]. Nephrology(Carlton),2007,12(6):576-581.
|
| 6 |
Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy [J]. Lancet,2002,360(9337):923-924.
|
| 7 |
Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study[J]. J Am Soc Nephrol,2003,14(7):1851-1857.
|
| 8 |
Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses [J].Nephrol Dial Transplant,2004,19(5):1305-1307.
|
| 9 |
Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy [J]. Kidney Int, 1999, 56(4):1534-1543.
|
| 10 |
Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy [J]. Am J Kidney Dis,2006,47(2):233-240.
|
| 11 |
陈意志, 李平, 胡婕, 等. 新型免疫抑制剂治疗特发性膜性肾病的Meta 分析[J]. 中华肾病研究电子杂志,2014,3(2):91-98.
|
| 12 |
Tang S,Leung JC,Chan LY,et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy[J]. Kidney Int,2005,68(2):802-812.
|
| 13 |
Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy [J]. Kidney Int,2010,77(6):543-549.
|
| 14 |
Liang Y, Zhang J, Liu D, et al. Retrospective study of mycophenolate mofetil treatment in IgA nephropathy with proliferative pathological phenotype [J]. Chin Med J (Engl), 2014, 127(1):102-108.
|
| 15 |
Liu X, Dewei D, Sun S, et al. Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone [J]. Int J Clin Pharmacol Ther,2014,52(2):95-102.
|
| 16 |
Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study [J]. Kidney Int,2004,65(5):1842-1849.
|
| 17 |
Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial [J]. Kidney Int,2006,70(4):732-742.
|
| 18 |
Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study [J]. Lupus,2010,19(11):1281-1289.
|
| 19 |
Bao H, Liu ZH,Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy [J]. J Am Soc Nephrol,2008,19(10):2001-2010.
|
| 20 |
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis [J]. N Engl J Med,2010,363(3):211-220.
|
| 21 |
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis [J]. N Engl J Med,2010,363(3):221-232.
|
| 22 |
Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement [J]. Nephrol Dial Transplant,2008,23(4):1307-1312.
|
| 23 |
Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis[J]. Ann Rheum Dis,2009,68(3):310-317.
|
| 24 |
Li X, Tian J, Wu J, et al. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study [J]. Clin Ther,2009,31(4):741-750.
|